Solid Biosciences (SLDB) Capital Expenditures (2017 - 2026)

Solid Biosciences has reported Capital Expenditures for 10 years, with the latest figure at $165000.0 in Q1 2026.

• Quarterly Capital Expenditures rose 30.95% year-over-year to $165000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $85000.0 (down 86.53% YoY) and the FY2025 annual result came in at $46000.0, down 92.97% from the prior year.
• Capital Expenditures improved to $165000.0 in Q1 2026 per SLDB's latest filing, from -$542000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $1.5 million in Q4 2023 and troughed at -$1.1 million in Q3 2022.
• A 5-year average of $171000.0 and a median of $165000.0 in 2026 frame the typical range for Capital Expenditures.
• The widest YoY moves for Capital Expenditures: up 1740.0% in 2022, down 2728.21% in 2022.
• Over 5 years, Capital Expenditures stood at $310000.0 in 2022, then surged by 388.71% to $1.5 million in 2023, then plunged by 59.21% to $618000.0 in 2024, then slumped by 187.7% to -$542000.0 in 2025, then surged by 130.44% to $165000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $165000.0, -$542000.0, and $588000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.